More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$3.01B
EPS
-1.16
P/E ratio
--
Price to sales
4.26
Dividend yield
--
Beta
1.39459
Previous close
$90.83
Today's open
$90.52
Day's range
$89.35 - $92.04
52 week range
$82.85 - $192.47
show more
CEO
Quentin S. Blackford
Employees
2400
Headquarters
San Francisco, CA
Exchange
Nasdaq Global Select
Shares outstanding
33618146
Issue type
Common Stock
Healthcare
Medical Equipment & Supplies
iRhythm Announces $100 Million Accelerated Share Repurchase Agreement
SAN FRANCISCO, Nov. 17, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it has entered into an accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank, National Association (JPMorgan) for $100 million of its common stock, as part of its previously announced $200 million share repurchase authorization.
GlobeNewsWire • 14 hours ago

IRHYTHM HOLDINGS, INC. INVESTIGATION: IRTC Securities Investors Encouraged to Contact Kirby McInerney LLP About Their Rights
NEW YORK--(BUSINESS WIRE)---- $IRTC #ClassActionLawsuit--The law firm of Kirby McInerney LLP is investigating potential claims against iRhythm Holdings, Inc. (“iRhythm” or the “Company”) (NASDAQ: IRTC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices. If you purchased or otherwise acquired iRhythm securities, please contact Lauren Molinaro of Kirby McInerney LLP by email at investigations@kmllp.com.
Business Wire • Nov 13, 2026

iRhythm Announces Approval of $200 Million Share Repurchase Program
SAN FRANCISCO, Nov. 11, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (Nasdaq: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that on November 10, 2026, its Board of Directors approved a share repurchase program with authorization to purchase up to $200 million of the company's outstanding common stock.
GlobeNewsWire • Nov 11, 2026

What iRhythm Technologies (IRTC) Said on Its Q3 Earnings Call
iRhythm Technologies NASDAQ: IRTC raised its 2026 revenue and profitability outlook after reporting third-quarter growth driven by its core Zio monitor business, even as demand for its Zio AT telemetry product fell short of expectations.
MarketBeat • Nov 6, 2026

IRTC Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into iRhythm Technologies, Inc. (IRTC)
A revenue shortfall against Wall Street consensus, flat Zio AT sales, and the Zio MCT FDA submission has now slipped into 2027. SueWallSt notifies investors of a pending investigation into potential securities law violations on behalf of investors who lost money.
PRNewsWire • Nov 6, 2026

iRhythm Holdings to Participate in Upcoming Investor Conferences
SAN FRANCISCO, Nov. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today announced that it will participate in the following investor conferences.
GlobeNewsWire • Nov 6, 2026

iRhythm Holdings, Inc. (IRTC) Q3 2026 Earnings Call Transcript
iRhythm Holdings, Inc. (IRTC) Q3 2026 Earnings Call Transcript
Seeking Alpha • Nov 6, 2026

iRhythm Holdings Announces Third Quarter 2026 Financial Results
SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company with a mission to create trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended September 30, 2026.
GlobeNewsWire • Nov 5, 2026

iRhythm Holdings, Inc. (IRTC) Q3 Earnings Surpass Estimates
iRhythm Holdings, Inc. (IRTC) came out with quarterly earnings of $0.82 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to a loss of $0.06 per share a year ago.
Zacks Investment Research • Nov 6, 2026

iRhythm Holdings, Inc. (IRTC) Earnings Expected to Grow: Should You Buy?
IRHYTHM HLDGS (IRTC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell iRhythm Holdings Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.